H.C. Wainwright analyst Douglas Tsao raised the firm’s price target on Biohaven to $63 from $50 and keeps a Buy rating on the shares post the Q4 results. The analyst says Biohaven’s diverse portfolio is progressing through multiple indications, but the firm is focused on its epilepsy, metabolic and IgG degrader platforms. It says near-term value-creating inflection catalysts for the company warrant investor attention.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BHVN:
- Biohaven price target raised to $55 from $35 at TD Cowen
- Biohaven reports Q4 non-GAAP EPS ($1.61), consensus ($1.41)
- Biohaven Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Developments
- JPMorgan biotech analysts to hold an analyst/industry conference call
- Biohaven price target raised to $56 from $32 at JPMorgan
